SCHEMBL6100643

SCHEMBL6100643

Fc1cccc(CN2CCN(c3cccc(OCc4ccncc4)n3)CC2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
HSD17B10 Q99714 1/20 0.56
HTT P42858 3/20 0.52
KDM4E B2RXH2 3/20 0.52
LMNA P02545 2/20 0.52
TSHR P16473 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
HPGD P15428 1/20 0.52
ALOX12 P18054 1/20 0.52
DRD2 P14416 3/20 0.49
DRD4 P21917 3/20 0.49
DRD3 P35462 3/20 0.49
NPC1 O15118 1/20 0.46
MAPT P10636 1/20 0.46
RAB9A P51151 1/20 0.46
MAPK1 P28482 1/20 0.45
CASP1 P29466 1/20 0.44
CASP4 P49662 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096996 0.89 KDM4E (0.52) ALDH1A1MEN1KMT2AHSD17B10HTT
SCHEMBL6100140 0.88 NPC1 (0.59) ALDH1A1MEN1KMT2AHTTKDM4E
SCHEMBL6099980 0.87 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AHTTKDM4E
SCHEMBL6097756 0.87 HTT (0.52) ALDH1A1HTTKDM4ELMNATSHR
SCHEMBL6931610 0.85 ALDH1A1 (0.59) ALDH1A1HTTKDM4ELMNATSHR
SCHEMBL6100319 0.85 HTT (0.49) ALDH1A1HTTKDM4ELMNATSHR
SCHEMBL6097304 0.83 POLB (0.52) ALDH1A1KMT2AHTTKDM4ELMNA
SCHEMBL6100825 0.82 KDM4E (0.59) ALDH1A1MEN1KMT2AHSD17B10HTT
SCHEMBL6099758 0.81 HRH3 (0.45) ALDH1A1MEN1KMT2AHTTKDM4E
SCHEMBL6099099 0.80 HTT (0.47) ALDH1A1HTTKDM4ELMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7009051-B2 4-(2-pyridyl) piperazines having 5HT7 receptor agonist activity PFIZER INC (US) 2006-03-07 US claimed
US-20040014769-A1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity PFIZER INC. 2004-01-22 US claimed
EP-1254905-B1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity PFIZER PROD INC (US) 2003-12-17 EP claimed
US-20030008880-A1 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity PFIZER INC. 2003-01-09 US claimed
EP-1254905-A1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity Pfizer Products Inc. (US) 2002-11-06 EP claimed
US-7009051-B2 4-(2-pyridyl) piperazines having 5HT7 receptor agonist activity PFIZER INC (US) 2006-03-07 US disclosed
US-20040014769-A1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity PFIZER INC. 2004-01-22 US disclosed
EP-1254905-B1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity PFIZER PROD INC (US) 2003-12-17 EP disclosed
US-20030008880-A1 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity PFIZER INC. 2003-01-09 US disclosed
EP-1254905-A1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity Pfizer Products Inc. (US) 2002-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014769-A1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity HTR7, HTR1A, HTR2C ALDH1A1 1531/4885MEN1 1333/4885KMT2A 2168/4885
US-20030008880-A1 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity HTR7, HTR1A, HTR2C ALDH1A1 1581/4885MEN1 1346/4885KMT2A 2310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.